Cabaletta Bio is trading 16.15% higher at $1.51 after its November 8 announcement of Phase 1/2 rese-cel results. - Presented at ACR Convergence on November 8–9, results showed one-year responses in all six dermatomyositis patients and remission in all five biopsied lupus nephritis patients. - Results reported a favorable safety profile across 71 patients. - Broader market strength may be supportive, but clinical data are the more direct explanation; trading volume was unavailable in the provided context.